UK pharma Clinigen is to buy the remaining rights to Novartis’ cancer drug Proleukin, in a deal worth up to $210 million. Clinigen already bought ex-US rights to Proleukin (aldesleukin ...

Iovance reported Q4'24 revenues of $25M from Proleukin, a 51% increase from the prior quarter, but Amtagvi revenues of 48.7M, were up just 16% from the prior quarter. Proleukin revenues could be a ...

During the quarter, the company generated total revenues of $0.7 million — entirely from product sales of its recently-acquired interleukin-2 (IL-2) product Proleukin (aldesleukin). The reported ...

Iovance currently has two marketed drugs in its portfolio, the IL-2 product Proleukin (aldesleukin) and the TIL therapy Amtagvi. While Proleukin is approved to treat metastatic renal cell ...